Alzheimer’s immunotherapy boosted by AbbVie deal – Financial Times
Financial Times |
Alzheimer’s immunotherapy boosted by AbbVie deal
Financial Times AbbVie has signed a deal with a biotech company to develop medicines that encourage the immune system to fight Alzheimer’s, as the drugmaker seeks to replicate an approach that has proven successful in treating cancer. The Chicago-based … A company that’s taking a new approach to tackling Alzheimer’s just landed a $225 million endorsementBusiness Insider UK |
|
Designer babies in the age of CRISPR
McGill Tribune A powerful gene-editing tool, known as CRISPR, has been developing, promising new approaches to treating various illnesses and even modification of children by their parents. Yet, it seems society still hasn’t addressed fears about the possible misuse … |
|
Cancer Physicians Find New Hope For Patients With Gene Therapy
WOSU Public Media A new treatment for a type of childhood cancer is the first FDA-approved use of gene therapy, working as a “living drug” that can use the body’s own immune system to kill cancer cells. Researchers hope the treatment can provides an alternative for … |
|
Cancer Physicians Find New Hope For Patients With Gene Therapy
WOSU Public Media A new treatment for a type of childhood cancer is the first FDA-approved use of gene therapy, working as a “living drug” that can use the body’s own immune system to kill cancer cells. Researchers hope the treatment can provides an alternative for … |
|
New CAR–T Therapy Offers Notable Results, Potential Payer Challenges
Atlantic Information Services, Inc. 7), the agency hit another milestone with the approval of the first chimeric antigen receptor T cell (CAR-T) therapy. Novartis Pharmaceuticals Corp.’s Kymriah (tisagenlecleucel) has shown impressive results in clinical trials, but payers will face a … The FDA has just approved the revolutionary genetic modification treatmentSSL |
pharmaphorum |
Spark’s Corrective Gene Therapy Could Be First to Cost $1 Million
Atlantic Information Services, Inc. If the FDA follows an advisory committee’s lead, the agency will approve a gene therapy that treats a rare form of blindness by early next year. Spark Therapeutics Inc.’s Luxturna (voretigene neparvovec) would be the first gene therapy in the United … Out of the darkness: new gene therapies for eye diseasespharmaphorum |